Mouse Metabolic Phenotyping Center (MMPC) at UC Davis

小鼠代谢表型中心(MMPC) 在 加州大学戴维斯分校(UCD) 摘要(总体) 加州大学戴维斯分校(UCD)的这份申请寻求基础资金，以继续其 小鼠代谢表型中心(MMPC)及其肠道微生物组的研究和开发 程序。MMPC-UCD的使命是通过提供 研究社区提供标准化、高质量的代谢和生理表型鉴定服务，以验证 并描述糖尿病、糖尿病并发症、肥胖和相关代谢紊乱的小鼠模型。 我们的中心由一个行政核心、一个动物关怀核心和3个表型核心组成： 内分泌学和新陈代谢核心，身体成分，体温调节，食物摄入行为核心， 并发症和病理学核心。在过去的5年里，我们的中心已经为 超过90个客户，产生了53份出版物和超过70万美元的节目收入 再投资于该中心，以扩大和加强对客户的服务。在这次更新中，我们的中心 打算扩展和利用过去的成功(例如，减肥手术模型、微生物组特征、 分析认知功能减退、饮食操控身体成分等)继续关注临床 相关且可翻译的小鼠模型。为回应来自研究界的意见，我们寻求 提供表型测试，这将有助于新的、精确指导的疾病诊断和 心理治疗。我们的中心将提供测量生理参数(例如，认知和大脑)的服务 新陈代谢)，评估环境影响(例如，宿主-肠道微生物组相互作用)，并确定 缓解因素(例如，锻炼)对客户的老鼠或我们为客户制作的小鼠模型的影响。我们的整体 目标是进行与资源相关的研究，开发技术并将其转化为新服务，以及培训 下一代研究人员使用突变小鼠模型研究糖尿病、肥胖症和相关疾病 代谢紊乱。为了实现这些目标，我们将1)为用户提供经过验证的高质量费用- 服务测试，并开发重要的内分泌学、新陈代谢、身体成分、 体温调节、心血管疾病、认知和运动；2)建立微生物组研究和 包括揭示微生物组在宿主新陈代谢中的作用的项目的开发计划， 生理和功能，定义微生物组对疾病预防和病理的影响，以及 探索微生物组与其代谢物之间的相互作用；以及3)提高对当前和 UCD独有的产品和服务的可用性、可获得性和有用性的新用户，特别是 手术模型、表型程序和从头开始的小鼠模型，以及研究工具的培训 研究代谢性疾病的发病机制。实现这些目标将把老鼠身上的研究转化为 促进对糖尿病、肥胖症和相关代谢紊乱的理解，以提高诊断水平 人类的治疗和预防策略。

MOUSE METABOLIC PHENOTYPING CENTER (MMPC) AT THE UNIVERSITY OF CALIFORNIA DAVIS (UCD) ABSTRACT (OVERALL) This application from the University of California Davis (UCD) seeks base funding to continue operations of its Mouse Metabolic Phenotyping Center (MMPC) and to expands its gut microbiome research and development program. The mission of the MMPC-UCD is to advance medical and biological research by providing the research community with standardized, high quality metabolic and physiologic phenotyping services to validate and characterize mouse models of diabetes, diabetic complications, obesity and related metabolic disorders. Our Center is made up of an Administrative Core, an Animal Care Core, and 3 Phenotyping Cores: Endocrinology and Metabolism Core, Body Composition, Thermoregulation, and Food Intake Behavior Core, and Complications and Pathology Core. Over the last 5 years, our Center has provided over 27,500 services to more than 90 clients resulting in 53 publications and program income of over $700,000 that has been reinvested into the Center to expand and enhance service offerings to clients. In this renewal, our Center intends to extend and leverage past successes (e.g, bariatric surgery models, microbiome characterization, analysis of cognitive decline, dietary manipulation of body composition, etc) to continue to focus on clinically relevant and translatable mouse models. In response to input from the research community, we seek to provide phenotyping tests that will contribute to new, precision-guided paradigms of disease diagnosis and therapy. Our Center will offer services to measure physiologic parameters (e.g., cognition and brain metabolism), assess environmental influences (e.g., host-gut microbiome interactions), and determine the impact of mitigating factors (e.g., exercise) in client's mice or in mouse models we make for clients. Our overall goal is to conduct resource-related research, develop and transform technologies into new services, and train the next generation of researchers using mutant mouse models for the study of diabetes, obesity, and related metabolic disorders. To achieve these goals, we will 1) provide users with validated and high quality fee-for- service tests, and to develop important new tests in endocrinology, metabolism, body composition, thermoregulation, cardiovascular disease, cognition, and exercise; 2) establish a Microbiome Research and Development Program incorporating projects that uncover the role of the microbiome in host metabolism, physiology and function, define the impact of the microbiome on disease prevention and pathology, and explore interactions between the microbiome and its metabolites; and 3) raise awareness among current and new users of the availability, accessibility, and usefulness of products and services unique to UCD, especially surgical models, phenotyping procedures, and de novo mouse models, and training in research tools to investigate mechanisms of metabolic disease. Achieving these goals will translate research in mice that advances the understanding of diabetes, obesity, and related metabolic disorders to improve diagnostics, therapeutics, and prevention strategies in humans.